Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Janssen Research & Development, LLC
Scientific Title
A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy